Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan - 24/07/21
Doi : 10.1016/j.jinf.2021.05.017
Shohei Yamamoto a, Akihito Tanaka b, Yusuke Oshiro b, Masamichi Ishii c, Hironori Ishiwari c, Maki Konishi a, Kouki Matsuda d, Mitsuru Ozeki b, Kengo Miyo c, Kenji Maeda d, Tetsuya Mizoue a, ⁎ 
, Wataru Sugiura e, Hiroaki Mitsuya f, Haruhito Sugiyama g, Norio Ohmagari h
, Wataru Sugiura e, Hiroaki Mitsuya f, Haruhito Sugiyama g, Norio Ohmagari h a Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
b Department of Laboratory Testing Center, Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
c Center for Medical Informatics Intelligence, National Center for Global Health and Medicine, Tokyo, Japan
d Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
e Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
f Research Institute, National Center For Global Health and Medicine, Tokyo, Japan
g Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
h Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Keywords : COVID-19, SARS-CoV-2, Immunoassay, Health personnel, Seropidemiologic studies, Japan
Le texte complet de cet article est disponible en PDF.
Plan
© 2021
Publié par Elsevier Masson SAS.
Vol 83 - N° 2
P. 237-279 - août 2021 Retour au numéro
Article précédent
- Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India
- Beena Philomina J, Bani Jolly, Neethu John, Rahul C. Bhoyar, Nisha Majeed, Vigneshwar Senthivel, Fairoz CP, Mercy Rophina, Bindhu Vasudevan, Mohamed Imran, Prasanth Viswanathan, V.R. Arvinden, Anoop Joseph, Mohit Kumar Divakar, Priyanka R Nair, Afra Shamnath, P. Jayesh Kumar, Abhinav Jain, P. Geetha, Anjali Bajaj, Samatha Mathew, Vishu Gupta, Srashti Jyoti Agrawal, Vinod Scaria, Sridhar Sivasubbu, Chandni Radhakrishnan
- Mucormycosis—A serious threat in the COVID-19 pandemic?
- Lukasz Szarpak, Francesco Chirico, Michal Pruc, Luiza Szarpak, Tomasz Dzieciatkowski, Zubaid Rafique
Bienvenue sur EM-consulte, la référence des professionnels de santé.